Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer's disease

Gareth Maher-Edwards, Carolyn Watson, John Ascher, Carly Barnett, Diane Boswell, John Davies, Manuel Fernandez, Alexander Kurz, Orazio Zanetti, Beth Safirstein, Juan Paul Schronen, Marina Zvartau-Hind, Michael Gold

Research output: Contribution to journalArticle

Abstract

Background Two previous studies of SB742457, a 5-hydroxytryptamine (5-HT6) receptor antagonist, suggested the efficacy of improvements in cognition and global outcome in Alzheimer's disease (AD). Methods Two randomized, placebo-controlled trials investigated SB742457 15 and 35 mg daily in subjects with mild-to-moderate AD (Mini-Mental Health State Examination [MMSE] 10-26). Study 1 (n = 576) investigated SB742457 and donepezil (5-10 mg daily) as monotherapy for 6 months. Study 2 (n = 684) investigated SB742457 in subjects who were maintained on donepezil. Coprimary endpoints at 24 weeks assessed cognition (AD Assessment Scale-Cognitive Subscale [ADAS-Cog]) and global outcome (Study 1: Clinician Interview-Based Impression of Change Plus Caregiver Input [CIBIC+]; Study 2: Clinical Dementia Rating-Sum of Boxes [CDR-SB]). Safety was assessed throughout. Results Both studies failed to achieve formal statistical significance for their primary objectives. Study 1: SB742457 monotherapy was not statistically significantly different from placebo on any endpoint. Donepezil improved CIBIC+ but not ADAS-Cog. Study 2: SB742457 35 mg showed statistically significant differences relative to placebo for ADAS-cog (weeks 12, 24, and 48, but not week 36), ADCS-ADL (weeks 12-36, but not week 48), and CDR-SB (week 12 only). Conclusion Neither study met the overall criteria for success, but as an adjunct to donepezil, SB742457 was associated with sustained improvements for up to 48 weeks in cognition and ADL, compared with donepezil alone. Clinical Trial Registration: Clinicaltrials.gov: Study 1 NCT00708552; Study 2 NCT00710684.

Original languageEnglish
Pages (from-to)23-36
Number of pages14
JournalAlzheimer's and Dementia: Translational Research and Clinical Interventions
Volume1
Issue number1
DOIs
Publication statusPublished - Oct 14 2015

Keywords

  • 5-HT antagonist
  • ADAS-Cog
  • Alzheimer's disease
  • CDR-SB
  • CIBIC+
  • Donepezil

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer's disease'. Together they form a unique fingerprint.

  • Cite this

    Maher-Edwards, G., Watson, C., Ascher, J., Barnett, C., Boswell, D., Davies, J., Fernandez, M., Kurz, A., Zanetti, O., Safirstein, B., Schronen, J. P., Zvartau-Hind, M., & Gold, M. (2015). Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 1(1), 23-36. https://doi.org/10.1016/j.trci.2015.04.001